scd

Voxelotor (GBT 440) is a novel hemoglobin S (HbS) polymerization inhibitor primarily used for the treatment of sickle cell disease (SCD) and a cytochrome P450 3A4 inhibitor. Voxelotor targets and covalently binds to the N-terminal valine of the HbS alpha chain, thereby stabilizing sickle cell hemoglobin (HbS).

GSK1940029 (SCD inhibitor 1) is an inhibitor of stearoyl-CoA desaturase (SCD).

Elemicin (Elemicine) is a constituent of several plant species' essential oils with anticholinergic effects in human.

A939572 is stearoyl-CoA desaturase1 (SCD1) inhibitor with IC50 values of <4 nM for mSCD1 and 37 nM for hSCD1.

SSI-4 is a Stearoyl CoA desaturase 1 (SCD1) inhibitor that can be labeled with carbon-11 (11C) for use as a ligand in small animal in vivo PET CT imaging studies of SCD1 [1].

SCD1 inhibitor-4 is stearoylCoA desaturase-1 (SCD1) inhibitor. SCD1 inhibitor-4 can be used for the research of diabetes.

SCD1 inhibitor-1 is a potent, liver-selective inhibitor of stearoyl-CoA desaturase-1 (SCD1).

SCD1 inhibitor-3 (ML-270) is a highly effective and orally available compound that inhibits SCD1 with remarkable safety. SCD1 inhibitor-3 demonstrates strong potential for research in metabolic diseases, including obesity, type II diabetes, and dyslipidemia, as well as various skin conditions like acne and cancer.

SCD1-IN-1, a potent inhibitor of SCD1 (IC50: 5.8 nM), is valuable in dermatologic research [1].

SCD1 Inhibitor is a novel stearoyl-CoA desaturase1 (SCD1) inhibitor.

Sphingolipid ceramide N-deacylase (SCDase) is an enzyme that catalyzes the cleavage of the N-acyl linkage between fatty acids and sphingosine bases in various glycosphingolipids, converting them into lysoglycosphingolipids [1].

SCD1/5-IN-1 (Compound 10), a selective SCD1/5 inhibitor, is utilized in the research of neurological diseases [1].

dWIZ-1 ((rac)-dWIZ-1) is a potent WIZ molecular gel degrader that recruits WIZ (ZF7) to the cereblon thereby inducing degradation and thus induction of haemoglobin fetalis (HbF) in erythroblasts, which can be used to study sickle cell disease (SCD).

CAY10566 shows excellent cellular activity in blocking the conversion of saturated long-chain fatty acid-CoAs (LCFA-CoAs) to monounsaturated LCFA-CoAs in HepG2 cells (IC50=7.9 nM or 6.8 nM). CAY10566 is a potent, orally bioavailable and selective stearoyl

PluriSIn 1 (NSC 14613) is an inhibitor of stearoyl-CoA desaturase (SCD1), the key enzyme in oleic acid biosynthesis, highlighting a unique role for lipid metabolism in hPSCs.

SLC13A5-IN-1 is a selective inhibitor of the sodium-citrate co-transporter (SLC13A5) that completely blocks the uptake of 14C-citrate, with an IC50 of 0.022 μM in HepG2 cells.

T-3764518 is a novel and potent inhibitor of stearoyl coenzyme A desaturase (SCD) with an IC50 of 4.7 nM.

XEN723 is a potent thiazolylimidazolidinone Stearoyl-CoA Desaturase (SCD1) inhibitor(IC50s of 45 and 524 nM in mouse and HepG2 cell, respectively).

BMS-564929 is a highly effective androgen receptor (AR) agonist that upregulates the expression and activity of lipogenic enzymes, reduces VAT content and lipid content, and downregulates the expression of acetyl-CoA carboxylase, FASN, and SCD.

MF-438 is an effective and orally bioavailable stearoyl-CoA desaturase 1 (SCD1) inhibitor (EC50: 2.3 nM for rSCD1).

Rovatirelin (also known as S-0373) is a novel synthetic compound that mimics the action of thyrotropin-releasing hormone (TRH). This compound exhibits a higher affinity for human TRH receptors (Ki=702nM) compared to taltirelin (Ki=3877nM). In acutely isolated norepinephrine neurons of the rat locus coeruleus (LC), rovatirelin enhances the firing of spontaneous action potentials. Additionally, rovatirelin increases motor activity and may offer potential therapeutic benefits as an oral treatment for patients with SCD.

MK-8245 analog is an analog of MK-8245 which is a liver-targeted Inhibitor of Stearoyl-CoA Desaturase (SCD). It is useful for the Treatment of Dyslipidemia and Diabetes.

MK-8245 is a liver-targeting SCD inhibitor for human SCD1 (IC50: 1 nM) and for rat mouse SCD1 (IC50: 3 nM), with anti-diabetic and anti-dyslipidemic function.

SW208108 is a tumor-specific irreversible inhibitor of stearoyl CoA desaturase (SCD).